# Nurix Therapeutics Reports $4.73 Q3 GAAP EPS and $673.1M Revenue

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/30562
Published: 2026-10-12T20:14:15.000Z
Updated: 2026-10-12T20:14:15.000Z
Section: Business

> Revenue rose 8,420.3% from a year earlier and exceeded estimates by $193.58 million. Cash, cash equivalents and marketable securities totaled $1.1 billion as of Aug. 31, 2026.

Nurix Therapeutics reported third-quarter GAAP earnings per share of $4.73 and revenue of $673.1 million, with both results exceeding market expectations for the period.

Earnings per share surpassed estimates by $1.64. Revenue increased 8,420.3% from a year earlier and came in $193.58 million above expectations.

Cash, cash equivalents and marketable securities totaled $1.1 billion as of Aug. 31, 2026, up from $592.9 million as of Nov. 30, 2025.

The report was published Oct. 12 at 4:08 p.m. ET (20:08 UTC).